• no-js

The mission of the MRC Weatherall Institute of Molecular Medicine (WIMM) is to undertake internationally competitive research into the processes underlying normal cell and molecular biology and to determine the mechanisms by which these processes are perturbed in inherited and acquired human diseases. It is also our mission to translate this research to improve human health. The WIMM is uniquely placed among biomedical institutes throughout the world in its pioneering vision of combining outstanding clinical research with excellent basic science. The WIMM Faculty currently includes an equal mixture of scientists and clinicians working together and in collaboration with the National Institute of Health Research, the NHS and commercial companies with the aim of improving the diagnosis and treatment of human diseases. The major topics of current research include haematology, immunology, stem cell biology, oncology and inherited human genetic diseases.

The Institute values communication with members of the broader scientific community and the general public and with the support of the MRC we have commissioned three short videos to explain our mission.

News

Academy of Medical Sciences Starter Grant Awarded

Academy of Medical Sciences Starter Grant Awarded

Posted 17/02/2015

Noémi Roy was awarded an Academy of Medical Sciences Starter Grant for Clinical Lecturers.  These grants are aimed at supporting Clinical Lecturers in strengthening their research experience at post-doctoral level.  Noémi will be working in Veronica Buckle’s lab, studying the phenotype of a CDAN1 conditional knock-out mouse in the haematopoietic system.  CDAN1 is one of the genes known to cause Congenital Dyserythropoietic Anaemia. 

 

MRC Developmental Pathway Funding Scheme grant awarded

MRC Developmental Pathway Funding Scheme grant awarded

Posted 03/02/2015

WIMM Professor Ahmed Ahmed, along with Martin Drysdale from the Beatson Institute in Glasgow and Stefan Knapp (TDI, Oxford) have been awarded a substantial DPFS (Developmental Pathway Funding Scheme) grant (~£1.9M) from the MRC.  The grant will support intensive medicinal chemistry efforts, structural biology and preclinical evaluation to develop novel small molecule inhibitor of SIK2 for ovarian cancer therapy.

 News Archive

 

Vacancies

Further Vacancies

WIMM Blog

A year in the life of a research institute: the WIMM blog celebrates its first birthday

birthdaycandles1
Just over a year ago, the WIMM Blog first appeared on the Weatherall Institute of Molecular Medicine’s webpage, tentatively re-posting an article that had originally been written for the MRC blog Insight. Today, the blog is a fully-fledged interactive site, and has had over two and half thousand hits in the last four months alone. Here we review the blog’s first year, and take a peek into what the future might hold…

WIMM Blog Archive